Anti-IgSF4 antibody and utilization of the same
US8048992B2 · kind B2 · utility
1Cited by
0References
6Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 22, 2006 |
| Grant date | Nov 1, 2011 |
| Priority date | — |
| Expiry date | Mar 8, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.